spacer
home > ebr > spring 2019 > details matter
PUBLICATIONS
European Biopharmaceutical Review

Details Matter

The transition from uni- to multicellular organisms was marked by an increase in the complexity of cell surface proteins that allowed intercellular communication and stable cell adhesion (1). The surfaceome (the collection of proteins residing at the cell surface) acts as the interface between a cell and its environment, mediating crucial cellular behaviours such as cell-cell communication, self and non-self recognition, and cell signalling. Additionally, the surfaceome largely dictates the shape, polarity, differentiation, and motility of cells. Given the crucial role of surface-associated proteins in every aspect of cellular life, they are, unsurprisingly, the molecular targets for roughly 70% of FDA approved drugs (2).

The aforementioned functions of the surfaceome are mediated through interactions of proteins in the cell membrane of the same cell (cis) and through interactions with proteins of neighbouring cells, the extracellular matrix, and circulating ligands (trans). The collection of cis and trans interactions is overall referred to as extracellular proteinprotein interactions (ePPIs). For a cell to adapt quickly in a changing microenvironment and respond fast to stimuli while retaining the necessary plasticity, ePPIs are usually transient with low affinities (μM to mM range) to allow for fast dissociation rates. Additionally, surface proteins have a few distinct properties compared to their intracellular counterparts. Firstly, correct folding of these proteins is largely dependent on an oxidising environment for the formation of disulphide bonds. Secondly, given that more than 90% of vertebrate surface proteins are glycosylated, correct folding also requires specialised chaperons and glycosylation machinery (3). Thirdly, membrane-spanning proteins are largely amphipathic due to hydrophilic glycans decorating the extracellular part and stretches of hydrophobic amino acids that span the membrane.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Maria P Pavlou received her PhD in translational proteomics from the Department of Laboratory Medicine and Pathobiology at University of Toronto, Canada. Upon PhD completion, Maria moved to Switzerland to pursue a postdoctoral fellowship in the Institute of Molecular Systems Biology at the Swiss Federal Institute of Technology (ETH) in Zürich, focussing on host-pathogen interactions. In 2017, she joined Dualsystems Biotech as a senior scientist, and, a year later, she was promoted to Chief Scientific Officer, leading the research team to develop further the LRC methodology and establish new services.

Dr Paul Helbling did his Master’s degree in biology at the University of Zürich, Switzerland, and obtained his PhD in developmental biology at ETH Zürich. After his PhD, he worked at the Foundation for Cardiovascular Research and organised clinical studies according to Good Clinical Practice. Paul then moved on to MDS Pharma Services, where he became responsible for the ligand binding group that specialised inthe analysis of biologics and antidrug antibodies. His next position was in business development at Solvias, responsible for southern Europe and Germany and opening new market territories in Turkey. Paul then became Head of Business Development at IBR, before joining the team at Dualsystems Biotech as CEO, focussing on identifying targets and off-targets on the living cells using liquid chromatographymass spectrometry.
spacer
Dr Maria P Pavlou
spacer
spacer
spacer
Dr Paul Helbling
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera announces a better drug deposition with RetroNose to enhance therapeutic efficacy of nasal treatments

After announcing a partnership with the Research Center for Respiratory Diseases (CEPR) of Inserm/University of Tours in April 2017, Nemera is happy to publish enhanced drug deposition results compared to classic nasal sprays with RetroNose.
More info >>

White Papers

Biosimilars In Emerging Markets: Is It A Level Playing Field?

PRA Health Sciences (PRA)

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >>

 
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Ireland’s premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement